Aurinia Pharmaceuticals Inc. (AUPH) |
| 15.05 -0.3 (-1.95%) 05-29 15:10 |
| Open: | 15.35 |
| High: | 15.37 |
| Low: | 15.03 |
| Volume: | 559,655 |
| Market Cap: | 1,935(M) |
| PE Ratio: | 7.07 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 16.76 |
| Resistance 1: | 15.86 |
| Pivot price: | 15.53 |
| Support 1: | 14.40 |
| Support 2: | 11.98 |
| 52w High: | 16.88 |
| 52w Low: | 7.285 |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Financials
| EPS | 2.160 |
| Book Value | 4.340 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.815 |
| Profit Margin (%) | 99.97 |
| Operating Margin (%) | 53.31 |
| Return on Assets (ttm) | 13.7 |
| Return on Equity (ttm) | 65.0 |
Company news
Fri, 22 May 2026
AUPH News | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
Wed, 20 May 2026
Aurinia (AUPH) Chief Legal Officer granted 115,541 performance stock units - Stock Titan
Wed, 20 May 2026
Aurinia (AUPH) COO receives 116,144 PSUs and 70,230 stock options - Stock Titan
Fri, 15 May 2026
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Raises Some Questions - simplywall.st
Thu, 07 May 2026
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress - BioSpace
Thu, 07 May 2026
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
